deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL NCT00177060

Topical Hydromorphone for Wound Healing

Sponsor: Hordinsky, Maria K., MD

Conditions Wound Healing
Interventions hydromorphone
Updated 7 times since 2017 Last updated: Feb 26, 2010 Started: Oct 31, 2003 Completion: May 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

No funding available.

This PHASE1/PHASE2 trial investigates Wound Healing and is currently terminated or withdrawn. Hordinsky, Maria K., MD leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

This is based on our published data that morphine is a powerful stimulant of angiogenesis and our preclinical study of wounds in rats which demonstrate that topical opioids (morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on hydromorphone which was more powerful than morphine as a wound-healer in the rat study.

This is based on our published data that morphine is a powerful stimulant of angiogenesis and our preclinical study of wounds in rats which demonstrate that topical opioids (morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on hydromorphone which was more powerful than morphine as a wound-healer in the rat study.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshotTerminated~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Nov 2019 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Jun 2018 — Nov 2019 [monthly]

    Terminated PHASE1_PHASE2

Show 2 earlier versions
  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hordinsky, Maria K., MD
Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations